The ability of a tumor to produce and respond to TNF (or another TNFSF death ligand) is vital for the anti-tumor effect of SMs, and tumors that lack either of these functions will most likely be resistant to SM treatment [17,20,109,110]. The gene discussed is TNF; the disease is neoplasm.